# OnCo record hrd-positive (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/hrd-positive/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "hrd-positive" ;
  schema:name "HRD-positive (genomic instability score)"@en ;
  schema:alternateName "HRD"@en, "HRD-positive"@en, "HRD positive"@en, "homologous recombination deficiency"@en, "genomic instability score"@en, "GIS"@en, "GIS >= 42"@en, "myChoice HRD"@en, "HRD score"@en, "genomic scar"@en ;
  schema:description "HRD-positive means the tumour's genome carries the scars of failed double-strand break repair (or a BRCA mutation), measured as a genomic instability score. In ovarian cancer it selects niraparib, and olaparib with bevacizumab, as first-line maintenance."@en ;
  schema:url <https://onco.cc/biomarkers/hrd-positive/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7f675e2-159c-490c-b6f4-3f16d9492b7d>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa> ;
  onco:tag "biomarker", "brca", "genome-wide" ;
  onco:related <https://onco.cc/biomarkers/brca-somatic/>, <https://onco.cc/biomarkers/brca-germline/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/> ;
  onco:drugs <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/mychoice-cdx/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/platinum-sensitivity/> .